New hope for Hard-to-Treat colorectal cancer: immunotherapy combo trial launches
Disease control
Recruiting now
This study tests a combination of two immunotherapy drugs (nadunolimab and toripalimab) in people with a type of advanced colorectal cancer that hasn't responded to standard chemotherapy. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. A…
Phase: PHASE1, PHASE2 • Sponsor: Dan Feng • Aim: Disease control
Last updated May 13, 2026 16:01 UTC